The Current Status of Alternatives to Animal Testing and Predictive Toxicology Methods Using Liver Microfluidic Biochips
详细信息 查看全文
- 作者：Jean Matthieu Prot (1)
Eric Leclerc (1) eric.leclerc@utc.fr - 关键词：Liver – ; Microfluidic biochips – ; PBPK models – ; Transcriptomics – ; Proteomics – ; Metabolomics – ; Cytomics – ; Alternative methods – ; Predictive toxicology
- 刊名：Annals of Biomedical Engineering
- 出版年：2012
- 出版时间：June 2012
- 年：2012
- 卷：40
- 期：6
- 页码：1228-1243
- 全文大小：992.3 KB
- 参考文献：1. Abraham, V. C., D. L. Taylor, and J. R. Haskins. High content screening applied to large-scale cell biology. Trends Biotechnol. 22:15–22, 2004.
2. Albrecht, D. R., G. H. Underhill, J. Resnikoff, A. Mendelson, S. N. Bhatia, and J. V. Shah. Microfluidics-integrated time-lapse imaging for analysis of cellular dynamics. Integr. Biol. 2:278–287, 2010.
3. Anderson, J., D. Chiu, J. McDonald, R. Jackman, O. Cherniavskaya, H. Wu, S. Whitesides, and G. Whitesides. Fabrication of topologically complex three-dimensional microfluidic systems in PDMS by rapid prototyping. Anal. Chem. 72:3158–3164, 2000.
4. Aninat, C., A. Piton, D. Glaise, T. Le Charpentier, S. Langouet, F. Morel, et al. Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab. Dispos. 34:75–83, 2006.
5. Baudoin, R., A. Corlu, L. Griscom, C. Legallais, and E. Leclerc. Trends in the development of microfluidic cell biochips for in vitro hepatotoxicity. Toxicol. In Vitro 21:535–544, 2007.
6. Baudoin, R., L. Griscom, J. M. Prot, C. Legallais, and E. Leclerc. Behavior of HepG2/C3A cell cultures in a microfluidic bioreactor. Biochem. Eng. J. 53:172–181, 2011.
7. Becker, H., and C. G盲rtner. Polymer microfabrication methods for microfluidic analytical applications. Electrophoresis 21:12–26, 2000.
8. Beger, R., J. Sun, and L. Schnackenberg. Metabolomics approaches for discovering biomarkers of drug-induced hepatotoxicity and nephrotoxicity. Toxicol. Appl. Pharmacol. 243:154–166, 2010.
9. Bhatia, S. N., M. L. Yarmush, and M. Toner. Controlling cell interactions by micropatterning in co-cultures: hepatocytes and 3T3 fibroblasts. J. Biomed. Mater. Res. 34:189–199, 1997.
10. Bhogal, N., C. Grindon, R. Combes, and M. Balls. Toxicity testing: creating a revolution based on new technologies. Trends Biotechnol. 23:299–307, 2005.
11. Blaauboer, B. J., and M. E. Andersen. The need for a new toxicity testing and risk analysis paradigm to implement REACH or any other large scale testing initiative. Arch. Toxicol. 81:385–387, 2007.
12. Blanchard, N., E. Alexandre, C. Abadie, T. Lav茅, B. Heyd, G. Mantion, D. Jaeck, L. Richert, and P. Coassolo. Comparison of clearance predictions using primary cultures and suspensions of human hepatocytes. Xenobiotica 35:1–15, 2005.
13. Blanchard, N., L. Richert, B. Notter, F. Delobel, P. David, P. Coassolo, and T. Lav茅. Impact of serum on clearance predictions obtained from suspensions and primary cultures of rat hepatocytes. Eur. J. Pharm. Sci. 23:189–199, 2004.
14. Boverhof, D. R., L. D. Burgoon, C. Tashiro, B. Sharratt, B. Chittim, J. R. Harkema, et al. Comparative toxicogenomic analysis of the hepatotoxic effects of TCDD in Sprague Dawley rats and C57BL/6 mice. Toxicol. Sci. 94:398–416, 2006.
15. Chao, P., T. Maguire, E. Novik, K. C. Cheng, and M. L. Yarmush. Evaluation of a microfluidic based cell culture platform with primary human hepatocytes for the prediction of hepatic clearance in human. Biochem. Pharmacol. 78:625–632, 2009.
16. Charati, S., and S. Stern. Diffusion of gases in silicone polymer: molecular dynamics simulations. Macromolecules 31:5529–5535, 1998.
17. Cheng, S., J. M. Prot, E. Leclerc, and F. Y. Bois. Zonation-related pathways in human hepatocellular carcinoma cells in dynamic vs. static culture microenvironments. BMC Genomics, 2011 (to appear).
18. Choucha-Snouber, L., L. Griscom, P. E. Poleni, F. Razan, C. Brochot, C. Aninat, A. Corlu, C. Legallais, and E. Leclerc. Liver kidney microfluidic bioreactor for cell coculture in drug studies. In: Proceedings of the Miniaturized Total Analysis System, μTAS, Conference 2010, Groningen, The Netherlands.
19. Claude, N., F. Goldfain-Blanc, and A. Guillouzo. La place des methods in silico, in vitro, in omic dans l’茅valuation de la s茅curit茅 des medicaments. Med. Sci. 25:105–110, 2009.
20. Domansky, K., W. Inman, J. Serdy, A. Dash, M. H. Lim, and L. G. Griffith. Perfused multiwell plate for 3D liver tissue engineering. Lab Chip 10:51–58, 2010.
21. Dorn, J. F., G. Danuser, and G. Yang. Computational processing and analysis of dynamic fluorescence image data. Methods Cell Biol. 85:497–538, 2008.
22. Dumas, M. E., R. Barton, A. Toye, O. Cloarec, C. Blancher, A. Rothwell, J. Fearnside, R. Tatoud, V. Blanc, J. Lindon, S. V. Mitchell, E. Holmes, M. I. McCarthy, J. Scott, D. Gauguier, and J. Nicholson. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc. Natl. Acad. Sci. USA 103:12511–12516, 2006.
23. Eisenbrand, G., B. Pool-Zobel, V. Baker, M. Balls, B. J. Blaauboer, A. Boobis, et al. Methods of in vitro toxicology. Food Chem. Toxicol. 40:193–236, 2002.
24. Eschbach, E., S. S. Chatterjee, M. Noldner, E. Gottwald, H. Dertinger, K. F. Weibezahn, and G. Knedlitschek. Microstructured scaffolds for liver tissue cultures of high cell density: morphological and biochemical characterization of tissue aggregates. J. Cell. Biochem. 95:243–255, 2005.
25. Fiehn, O., J. Kopka, P. D枚rmann, T. Altmann, R. N. Trethewey, and L. Willmitzer. Metabolite profiling for plant functional genomics. Nat. Biotechnol. 18:1157–1161, 2000.
26. Figeys, D. Combining different ‘omics’ technologies to map and validate protein–protein interactions in humans. Brief Funct Genomic Proteomics 2:357–365, 2004.
27. Gibney, M., M. Walsh, L. Brennan, H. Roche, B. German, and B. van Ommen. Metabolomics in human nutrition: opportunities and challenges. Am. J. Clin. Nutr. 82:497–503, 2005.
28. Greim, H. Toxicological comments to the discussion about REACH (H. Greim, M. Arand, H. Autrup, H.M. Bolt, J. Bridges, E. Dybing, R. Glomot, V. Foa, R. Schulte-Hermann, Arch Toxicol 2006, 80: 121–124). Reply to the letter to the editor: the need for a new toxicity testing and risk analysis paradigm to implement REACH or any other large scale testing initiative, by B.J. Blaauboer and M.E. Andersen (Arch Toxicol 2007, 81: 385–387). Arch. Toxicol. 80:121–124, 2007.
29. Griffin, S. J., and J. B. Houston. Prediction of in vitro intrinsic clearance from hepatocytes: comparison of suspensions and monolayer cultures. Drug Metab. Dispos. 33:115–120, 2005.
30. Griffith, L., and G. Naughton. Tissue engineering—current challenges and expanding opportunities. Science 295:1009–1014, 2002.
31. Gripon, P., S. Rumin, S. Urban, J. Le Seyec, D. Glaise, I. Cannie, et al. Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl. Acad. Sci. USA 99:15655–15660, 2002.
32. Haenen, B., C. Rompelberg, K. Van Twillert, M. Hamzink, J. Dormans, and J. Van Eljkeren. Utility of rat liver slices to estimate hepatic clearance for application in physiologically based pharmacokinetic modeling: a study with tolbutamide, a compound with low extraction efficiency. Drug Metab. Dispos. 30:307–313, 2001.
33. Haney, S. A., P. LaPan, J. Pan, and J. Zhang. High-content screening moves to the front of the line. Drug Discov. Today 11:889–894, 2006.
34. Hartung, T., and C. Rovida. Chemical regulators have overreached. Nature 460:1080–1081, 2009.
35. Herrera, G., L. Diaz, A. Martinez-Romero, A. Gomes, E. Villamon, R. C. Callaghan, et al. Cytomics: a multiparametric, dynamic approach to cell research. Toxicol. In Vitro 21:176–182, 2007.
36. Hewitt, N. J., K. U. B眉hring, J. Dasenbrock, J. Haunschild, B. Ladstetter, and D. Utesch. Studies comparing in vivo:in vitro metabolism of three pharmaceutical compounds in rat, dog, monkey, and human using cryopreserved hepatocytes, microsomes, and collagen gel immobilized hepatocyte cultures. Drug Metab. Dispos. 29:1042–1050, 2001.
37. Houston, J. B. Relevance of in vitro kinetic parameters to in vivo metabolism of xenobiotics. Toxicol. In Vitro 8:507–512, 1994.
38. Houston, J. B., and D. J. Carlile. Prediction of hepatic clearance from microsomes, hepatocytes and liver slices. Drug Metab. Rev. 29:891–922, 1997.
39. Ito, K., and J. B. Houston. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm. Res. (NY) 21:785–792, 2004.
40. Iwatsubo, T., N. Hirota, T. Ooie, H. Suzuki, N. Shimada, K. Chiba, T. Ishizaki, C. E. Green, C. A. Tyson, and Y. Sugiyama. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. 73:147–171, 1997.
41. Kane, B. J., M. J. Zinner, M. L. Yarmush, and M. Toner. Liver-specific functional studies in a microfluidic array of primary mammalian hepatocytes. Anal. Chem. 78:4291–4298, 2006.
42. Kanehisa, M., S. Goto, M. Furumichi, M. Tanabe, and M. Hirakawa. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res. 38:355–360, 2010.
43. Khetani, S. R., and S. N. Bhatia. Microscale human liver tissue for drug development. Nat. Biotechnol. 26:120–126, 2008.
44. Kidambi, S., R. Yarmush, E. Novik, P. B. Chao, M. L. Yarmush, and Y. Nahmias. Oxygen-mediated enhancement of metabolism, functional polarization, gene expression, and drug clearance in co-cultures of primary hepatocytes. PNAS 106:15714–15719, 2009.
45. Kimura, H., H. Nakayama, T. Yamamoto, Y. Sakai, and T. Fujii. Development of on chip co culture system for cytotoxicity test using Caco-2 and HepG2. IEEJ 129:252–258, 2009.
46. Kimura, H., T. Yamamoto, H. Sakai, Y. Sakai, and T. Fujii. An integrated microfluidic system for long-term perfusion culture and on-line monitoring of intestinal tissue models”. Lab Chip 8:741–746, 2008.
47. Korn, K., and E. Krausz. Cell-based high-content screening of small-molecule libraries. Curr. Opin. Chem. Biol. 11:503–510, 2007.
48. Leclerc, E., Y. Sakai, and T. Fujii. Cell culture in 3-dimensional microfluidic structure of PDMS (polydimethylsiloxane). Biomed. Microdev. 5(2):109–114, 2003.
49. Leclerc, E., Y. Sakai, and T. Fujii. Perfusion culture of fetal human hepatocytes in microfluidic-environments. Biochem. Eng. J. 20:143–148, 2004.
50. Leclerc, E., Y. Sakai, and T. Fujii. Microfluidic PDMS (polydimethylsiloxane) bioreactors for large scale culture of hepatocytes. Biotech. Prog. 20:750–755, 2004.
51. Lee, P., T. Gaige, and P. Hung. Microfluidic systems for live cell imaging. Methods Cell Biol. 102:77–103, 2011.
52. Lee, P., N. Ghorashian, T. Gaige, and P. Hung. Microfluidic system for automated cell based assays. J. Assoc. Lab. Autom. 12:363–367, 2007.
53. Lee, S., and B. J. Howell. High-content screening: emerging hardware and software technologies. Methods Enzymol. 414:468–483, 2006.
54. Lee, M. Y., R. A. Kumar, S. M. Sukumaran, M. G. Hogg, D. S. Clark, and J. S. Dordick. Three-dimensional cellular microarray for high-throughput toxicology assays. Proc. Natl Acad. Sci. USA 105:59–63, 2008.
55. Ma, B., G. Zhang, J. Qin, and B. Lin. Characterization of drug metabolites and cytotoxicity assay simultaneously using an integrated microfluidic device. Lab Chip 9:232–238, 2009.
56. Madalinski, G., E. Godat, S. Alves, D. Lesage, E. Genin, P. Levi, J. Labarre, J. C. Tabet, E. Ezan, and C. Junot. Direct introduction of biological samples into a LTQ-Orbitrap hybrid mass spectrometer as a tool for fast metabolome analysis. Anal. Chem. 80:3291–3303, 2009.
57. Mahler, G. J., M. B. Esch, R. P. Glahn, and M. L. Shuler. Characterization of a gastrointestinal tract microscale cell culture analog used to predict drug toxicity. Biotechnol. Bioeng. 104:193–205, 2009.
58. Midwoud, P. M., G. M. M. van Groothuis Merema, M. T. Merema, and E. Verpoorte. Microfluidic biochip for the perifusion of precision-cut rat liver slices for metabolism and toxicology studies. Biotech. Bioeng. 105:184–194, 2010.
59. Midwoud, P. M., M. T. van Merema, E. Verpoorte, and G. M. M. Groothuis. A microfluidic approach for in vitro assessment of interorgan interactions in drug metabolism using intestinal and liver slices. Lab Chip 10:2778–2786, 2010.
60. Nicholson, J. K., J. Connelly, J. C. Lindon, and E. Holmes. Metabonomics: a platform for studying drug toxicity and gene function. Nat. Rev. Drug Discov. 1:153–161, 2002.
61. Nicholson, J. K., J. C. Lindon, and E. Holmes. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29:1181–1189, 1999.
62. Novik, E., T. J. Maguire, P. Chao, K. C. Cheng, and M. L. Yarmush. A microfluidic hepatic coculture platform for cell-based drug metabolism studies. Biochem. Pharmacol. 79:1036–1044, 2010.
63. Paine, S., A. Parker, P. Gardiner, P. Webborn, and R. Riley. Prediction of the pharmacokinetics of atorvastatin, cerivastatin, and indomethacin using kinetic models applied to isolated rat hepatocytes. Drug Metab. Dispos. 36:1365–1374, 2008.
64. Pang, K. S., and M. Rowland. Hepatic clearance of drugs. II. Experimental evidence for acceptance of the “well-stirred” model over the “parallel tube” model using lidocaine in the perfused rat liver in situ preparation. J. Pharmacokinet. Biopharm. 5:655–680, 1977.
65. Pang, K. S., and M. Rowland. Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J. Pharmacokinet. Biopharm. 5:625–653, 1977.
66. Paran, Y., M. Ilan, Y. Kashman, S. Goldstein, Y. Liron, B. Geiger, et al. High-throughput screening of cellular features using high-resolution light-microscopy; application for profiling drug effects on cell adhesion. J. Struct. Biol. 158:233–243, 2007.
67. Pelkonen, O., and M. Turpeinen. In vitro-in vivo extrapolation of hepatic clearance: biological tools, scaling factors, model assumptions and correct concentrations. Xenobiotica. 37:1066–1089, 2007.
68. Powers, M. J., D. Janigan, K. E. Wack, C. S. Baker, D. B. Stolz, and L. Griffith. Functional behavior of primary rat liver cells in a three-dimensional perfused microarray bioreactor. Tissue Eng. 8:499–508, 2002.
69. Prot, J. M., C. Aninat, L. Griscom, F. Razan, C. Brochot, C. Guguen Guillouzo, C. Legallais, A. Corlu, and E. Leclerc. Improvement of HepG2/C3a cell functions in a microfluidic biochip. Biotechnol. Bioeng. 108:1704–1715, 2011.
70. Prot, J. M., A. S. Briffaut, F. Letourneur, P. Chafey, F. Merlier, Y. Grandvalet, C. Legallais, and E. Leclerc. Integrated proteomic and transcriptomic investigation highlights original insight into paracetamol toxicity in liver biochip. PLoS One 6:e21268, 2011.
71. Prot, J. M., A. Bunescu, B. Elena-Hermann, C. Aninat, L. Choucha-Snouber, L. Griscom, F. Bois, C. C茅cile Legallais, C. C茅line Brochot, A. Anne Corlu, M. D. Dumas, and E. Leclerc. Alternative method in predictive toxicology using systemic biology on chip: application to acetaminophen injury. Toxicol. Appl. Pharmacol., 2011 (to appear).
72. Prot, J. M., O. Videau, C. Brochot, C. Legallais, H. Benech, and E. Leclerc. A cocktail of metabolic probes demonstrates the relevance of primary human hepatocyte cultures in a microfluidic biochip for pharmaceutical drug screening. Int. J. Pharm. 408:67–75, 2011.
73. Riley, R., D. F. McGinnity, and R. P. Austn. A unified model for predicting human hepatic, metabolic clearance from in vitro intrinsic clearance data in hepatocyte and microsomes. Drug Metab. Dispos. 33:1304–1311, 2005.
74. Sheikh-Bahaei, S., S. H. J. Kim, S. Sheikh-Bahaei, and C. A. Hunt. Understanding the role of liver zonation in toxin elimination. Int. J. Intell. Control Syst. 14:33–40, 2009.
75. Shibata, Y., H. Takahashi, M. Chiba, and Y. Ishii. Prediction of hepatic clearance and availability by cryopreserved human hepatocytes: an application of serum incubation method. Drug Metab. Dispos. 30:892–896, 2002.
76. Shibata, Y., H. Takahashi, and Y. Ishii. A convenient in vitro screening method for predicting in vivo drug metabolic clearance using isolated hepatocytes suspended in serum. Drug Metab. Dispos. 28:1518–1523, 2000.
77. Shintu, L., R. Baudoin, V. Navratil, J. M. Prot, C. Pontoizeau, M. Defernez, B. Blaise, C. Domange, A. P茅ry, P. Toulhoat, C. Legallais, C. Brochot, E. Leclerc, and M. E. Dumas. Metabolomics-on-a-chip and predictive systems toxicology in microfluidic. Bioartificial organs. Anal. Chem., 2011 (to appear).
78. Sivaraman, A., J. K. Leach, S. Townsend, T. Iida, B. J. Hogan, D. B. Stolz, R. Fry, L. D. Samson, S. R. Tannenbaum, and L. G. Griffith. A microscale in vitro physiological model of the liver: predictive screens for drug metabolism and enzyme induction. Curr. Drug Metab. 6:569–592, 2005.
79. Sung, J. H., C. Kam, and M. J. Shuler. A microfluidic device for a pharmacokinetic–pharmacodynamic (PK-PD) model on a chip. Lab Chip 10:446–455, 2010.
80. Tilles, A., H. Baskaran, P. Roy, M. Yarmush, and M. Toner. Effects of oxygenation and flow on the viability and function of rat hepatocytes cocultured in a microchannel flat-plate bioreactor. Biotech. Bioeng. 73:379–389, 2001.
81. Toh, Y. C., T. C. Lim, D. Tai, G. Xiao, D. van Noort, and H. Yu. A microfluidic 3D hepatocyte chip for drug toxicity testing. Lab Chip 9:2026–2031, 2009.
82. Viravaidya, K., and M. L. Shuler. Incorporation of 3T3-L1 cells to mimic bioaccumulation in a microscale cell culture analog device for toxicity studies. Biotechnol. Prog. 20:590–597, 2004.
83. Walker, G. M., H. C. Zeringue, and D. J. Beebe. Microenvironment design considerations for cellular scale studies. Lab Chip 4:91–97, 2004.
84. Wood, D. K., D. M. Weingeist, S. N. Bhatia, and B. P. Engelward. Single cell trapping and DNA damage analysis using microwell arrays. PNAS 107:10008–10013, 2010.
85. Yu, H., I. Meyvantsson, I. A. Shkel, and D. J. Beebe. Diffusion dependent cell behavior in microenvironments. Lab Chip 5:1089–1095, 2005.
86. Zhang, S., W. Tong, B. Zheng, T. Susanto, L. Xia, C. Zhang, A. Ananthanarayanan, X. Tuo, R. Sakban, R. Jia, C. Iliescu, K. H. Chai, M. McMillian, S. Shen, H. Leo, and H. Yu. Robust high-throughput sandwich cell-based drug screening platform. Biomaterials 32:1229–1241, 2011.
87. Zhang, C., Z. Zhao, N. Abdul Rahim, D. van Noort, and H. Yu. Towards a human-on-chip: culturing multiple cell types on a chip with compartmentalized microenvironments. Lab Chip 9:3165–3312, 2009.
88. Zuegge, J., G. Schneider, P. Coassolo, and T. Lave. Prediction of hepatic metabolic clearance: comparison and assessment of prediction models. Clin. Pharmacokinet. 40:553–563, 2001. - 作者单位：1. CNRS UMR 6600, Laboratoire de Biom茅canique et Bioing茅nierie, Universit茅 de Technologie de Compi猫gne, Compi猫gne, France
- 刊物类别：Biomedical and Life Sciences
- 刊物主题：Biomedicine
Biomedicine
Biomedical Engineering
Biophysics and Biomedical Physics
Mechanics
Biochemistry - 出版者：Springer Netherlands
- ISSN：1573-9686
文摘
In this paper, we will consider new in vitro cell culture platforms and the progress made, based on the microfluidic liver biochips dedicated to pharmacological and toxicological studies. Particular emphasis will be given to recent developments in the microfluidic tools dedicated to cell culture (more particularly liver cell culture), in silico opportunities for Physiologically Based PharmacoKinetic (PBPK) modelling, the challenge of the mechanistic interpretations offered by the approaches resulting from “multi-omics” data (transcriptomics, proteomics, metabolomics, cytomics) and imaging microfluidic platforms. Finally, we will discuss the critical features regarding microfabrication, design and materials, and cell functionality as the key points for the future development of new microfluidic liver biochips.